Pasithea director granted 152,783 stock options

Pasithea Therapeutics Corp. director Lawrence Steinman received a grant of stock options as part of equity compensation.

Rhea-AI Filing Summary

Pasithea Therapeutics Corp. director Lawrence Steinman received a grant of stock options as part of equity compensation. The award covers 152,783 stock options for common stock with an exercise price of $0.841 per share and an expiration date in 2036.

These options vest in full on the one-year anniversary of the grant date if he remains a director through that date, and will fully vest earlier upon a Change in Control as defined in the company’s 2023 Stock Incentive Plan.

Insider Trade Summary

Grant/Award: 152,783 shares

Grant/Award 1 txn

Insider STEINMAN LAWRENCE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	152,783	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 152,783 contracts (Direct)

Footnotes (1)

1. F1. The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan).

Key Figures

Stock options granted: 152,783 options Exercise price: $0.841 per share Underlying shares: 152,783 shares +1 more

4 metrics

Stock options granted 152,783 options Director award under 2023 Stock Incentive Plan

Exercise price $0.841 per share Strike price for underlying common stock

Underlying shares 152,783 shares Common stock underlying the option award

Expiration date April 30, 2036 Option term end date

Key Terms

Stock Option, 2023 Stock Incentive Plan, Change in Control, vest in full

4 terms

Stock Option financial

"The option (the "Option") award was made in accordance with the terms"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2023 Stock Incentive Plan financial

"made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended"

Change in Control financial

"provided further, that the shares underlying the Option will fully vest upon a Change in Control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

vest in full financial

"underlying the Option will vest in full upon the one-year anniversary of the date of grant"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pasithea Therapeutics (KTTA) report for Lawrence Steinman?

Pasithea Therapeutics reported that director Lawrence Steinman received a grant of 152,783 stock options. The options are a compensation award, not an open-market purchase or sale, and give him the right to buy common shares at a fixed exercise price.

How many Pasithea (KTTA) stock options were granted and at what exercise price?

The award consists of 152,783 stock options for Pasithea common stock with an exercise price of $0.841 per share. This price is the cost per share Steinman must pay to exercise the options and acquire the underlying common shares.

When do Lawrence Steinman’s Pasithea (KTTA) stock options vest?

The options will vest in full one year after the grant date, provided Steinman remains a director through that date. They also fully vest upon a Change in Control of Pasithea, as defined in the company’s 2023 Stock Incentive Plan.

What is the expiration date of the Pasithea (KTTA) stock options granted to Lawrence Steinman?

The granted stock options have an expiration date in 2036, specifically April 30, 2036. After this date, any unexercised options will lapse, meaning Steinman would no longer be able to buy Pasithea common shares under this award.

Is the Pasithea (KTTA) insider transaction a market buy or a compensation grant?

This filing reflects a compensation-related grant, not a market buy or sale. The transaction code is “A” for an award, and the options were issued under Pasithea’s 2023 Stock Incentive Plan at no upfront purchase price per option.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 04:42 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STEINMAN LAWRENCE

(Last) (First) (Middle)

1111 LINCOLN ROAD

SUITE 500

(Street)

MIAMI BEACH FLORIDA 33139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pasithea Therapeutics Corp. [ KTTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.841	05/01/2026		A		152,783		(1)	04/30/2036	Common Stock	152,783	$0	152,783	D

Explanation of Responses:

1. The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan).

	/s/ Lawarence Steinman	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)